PureTech Health plc - 02 Jul 2024 Form 4 Insider Report for Akili, Inc.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
08 Jul 2024, 19:42:32 UTC
Prior SEC filing
21 Sep 2023
Next SEC filing
30 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
PureTech Health LLC, By: /s/ Bharatt Chowrira, Chief Executive Officer

Key filing fact

PureTech Health plc filed Form 4 for Akili, Inc. on 08 Jul 2024.

Key facts

  • This page summarizes PureTech Health plc's Form 4 filing for Akili, Inc..
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 08 Jul 2024, 19:42.

Change

  • Previous filing in this sequence was filed on 21 Sep 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKLI transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares
-12,527,477
Change %
-100%
Price
Shares after
0
Date
02 Jul 2024
Ownership
See footnote
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

PureTech Health plc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent"), and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"). Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time"), with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Person was converted into the Offer Price.

Footnote F2

PureTech Health LLC is the record holder of all of the securities reported in this Form 4. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech Health LLC.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .